By Michael Smith
May 22, 2014
The evidence base for one of the star hepatitis C drugs is poor and the guidelines for its use are flawed, according to a report prepared for the National Association of Medicaid Directors.
According to the report, studies of sofosbuvir (Sovaldi) are generally of poor quality, mostly directed by the drug’s maker, and don’t answer key questions, including whether the drug is better and safer than the current standard of care.
The only available guidelines for its use — guidelines created by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America — are “methodologically flawed,” according to the report, which was prepared by the Center for Evidence-Based Policy at Oregon Health and Science University in Portland.